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X‑ray inactivation of RNA 
viruses without loss of biological 
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In the event of an unpredictable viral outbreak requiring high/maximum biosafety containment 
facilities (i.e. BSL3 and BSL4), X‑ray irradiation has the potential to relieve pressures on conventional 
diagnostic bottlenecks and expediate work at lower containment. Guided by Monte Carlo modelling 
and in vitro 1‑log10 decimal‑reduction value (D‑value) predictions, the X‑ray photon energies required 
for the effective inactivation of zoonotic viruses belonging to the medically important families of 
Flaviviridae, Nairoviridae, Phenuiviridae and Togaviridae are demonstrated. Specifically, it is shown 
that an optimized irradiation approach is attractive for use in a multitude of downstream detection 
and functional assays, as it preserves key biochemical and immunological properties. This study 
provides evidence that X‑ray irradiation can support emergency preparedness, outbreak response 
and front‑line diagnostics in a safe, reproducible and scalable manner pertinent to operations that are 
otherwise restricted to higher containment BSL3 or BSL4 laboratories.
Climate change, increases in population density, deforestation and urbanization are altering the geographical 
range of vectors that transmit dangerous viral pathogens, so promoting the spillover and emergence of zoonotic 
diseases into new regions and placing immunologically naïve populations at  risk1,2. A significant proportion of 
these emerging zoonosis are RNA viruses which present characteristically high transmission rates, are subject 
to unpredictable evolutionary change and cause high-consequence infectious diseases (HCIDs) in humans. 
Some notable examples include avian influenza (AI), Ebola virus (EBOV), severe acute respiratory syndrome 
coronavirus (SARS-CoV), West Nile virus and Zika virus (ZIKV) which have all caused unprecedented epidem-
ics across several countries, and in many instances  death3 or congenital  disease4, while exerting acute pressures 
on public health infrastructures and local  economies5. Incidences for such HCIDs are predicted to increase as 
population density, urbanization and climate equilibria continue to  fluctuate6–10. These relatively recent events, 
including the current emergence of COVID-1911,12 highlight the need for effective and reproducible workflows 
that permit safe, scalable and rapid pathogen inactivation, suitable for a range of downstream pathogen detec-
tion and intervention strategies.
Established methodologies for virus inactivation include  chemical13–15,  thermal16,  ultraviolet17,  plasma18, 
electron  bombardment19 and radiological  sources20,21 which can all have either selective or limited downstream 
applications. X-ray irradiation is an alternative to chemical and thermal approaches which both have known 
detrimental effects on the biological integrity of  samples22–24. It does not require the addition of exogenous 
toxic or volatile chemicals and does not induce notable thermal expansion within the sample. In contrast to UV, 
plasma and electron bombardment, high energy X-rays (≥ 1 keV) are composed of highly penetrative photons 
that traverse multiple layers of packaging in a similar manner to gamma radiation. Compared to gamma radia-
tion, however, X-ray sources do not suffer from radio-isotopic half-life decay or the same security implications 
that are associated with the use of ‘live’ radiological sources. Energy-spectra and dose rates are also more tunable 
with X-rays than with gamma sources.
The damage caused by photons is a consequence of target matter ionization and the disruption that this entails 
for the biological system, both directly via molecular break-up and indirectly via subsequent ionization and 
endogenous free-radical chemical reactions. At X-ray energies from ~ 1 keV up to a ~ few 10 s keV, photoelectric 
absorption is the primary interaction, in which the photon is absorbed by the atom and an electron is ejected. 
OPEN
1National Infection Service, Public Health England, Porton Down SP4 0JG, UK. 2Centre for Chemical, Radiation 
and Environmental Hazards, Public Health England, Chilton OX11 0RQ, UK. 3CBR Division, Defense and Science 
Technology Laboratories, Porton Down SP4 0JG, UK. 4Faculty of Infectious and Tropical Diseases, London School 
of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. *email: Babak.Afrough@phe.gov.uk
2
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21431  | https://doi.org/10.1038/s41598-020-77972-5
www.nature.com/scientificreports/
From a ~ few 10 s keV to a ~ few 10 s MeV, Compton scatter dominates, in which an electron is ejected but the 
photon is not absorbed and can hence cause additional ionization elsewhere in the sample. Above ~ 1.25 meV, 
electron–positron pair production processes can occur, and at higher energies still photonuclear, photo-disin-
tegration and other ‘exotic’ processes can begin to  arise25. In all cases, relaxation processes within the ionized 
atom (e.g. Auger and Coster-Kronig electron emission, fluorescence photons etc.) further contribute to the 
transmission of energy within the sample. The precise energy ranges above which one process dominates over 
another depend on the effective atomic number (Z) of the  material26. The amount of energy transferred from 
the field to the material is quantified by the absorbed dose, defined as the energy deposited in a given volume 
divided by its  mass27.
The probability that a photon interacts with a given atom generally decreases with increasing  energy28, sug-
gesting that lower energy X-rays are likely to be more efficient than more penetrating X-ray or gamma sources in 
the context of biological inactivation. However, and as an inevitable consequence, photon penetration decreases 
with decreasing energy, leading to potential dose gradients within samples. This implies that determination of 
the optimum X-ray energy for biological inactivation of macroscopic samples is non-trivial. Soft X-rays (1 to 
10 keV) have been shown to have some value in the inactivation of both  enveloped29 and non-enveloped  viruses30 
without causing excessive damage to antigenic properties as previously demonstrated using pathogenic bacterial 
 models31,32.
This study defines the amount and type of X-ray radiation required to produce replication deficient ZIKV 
(genus Flavivirus), Hazara virus (HAZV, genus Orthonairovirus), Bebaru virus (BEBV, genus Alphavirus) and 
Rift Valley Fever virus (RVFV, genus Phlebovirus), and provides D-values to achieve their respective controlled 
inactivation. The viruses selected here span a range of genomic arrangements and physical structural variants 
which are surrogates for higher risk group viruses that cause HCIDs e.g. Omsk hemorrhagic fever, Crimean-
Congo Hemorrhagic Fever and Chikungunya fever diseases. Using D-values defined here, evidence of comparable 
inactivation efficacy of X-rays to gamma radiation with retention of key biochemical and immunological charac-
teristics is presented, for use in downstream applications requiring high-fidelity nucleic acid or protein substrates.
Results
Low‑energy X‑rays produced by bremsstrahlung are responsible for virus inactivation effi-
cacy. To characterize the energy distributions of the photon fields for virus irradiation, Monte Carlo (MC) 
models of the X-ray source and irradiation chamber environment fitted to a MultiRad 225 Irradiator were devel-
oped using the general-purpose radiation transport code MC N-Particle (MCNP) version 6.133, designed to 
track many particle types over broad ranges of energies. Setting the tube potential to 220 keV and current to 
18.2 mA within the model, X-ray photon energies and dose rates for the irradiation of liquid virus samples 
through multi-layered packaging were modelled using an unfiltered beam, and 0.2, 0.5 or 2.0 mm aluminum 
(Al) or 0.3 mm copper (Cu) filters. The dose rates were calculated by the use of ‘kerma tallies’ (average kinetic 
energy released per unit mass), with equivalence between absorbed dose and kerma assumed; this assumption 
was justified from a consideration of the physical geometry of the irradiation chamber and sample set-up, and 
the maximum expected  ranges34 of any secondary electrons that might be produced. Conversion to absolute 
dose rates from the relative ‘per-source-electron’ normalization applied by default by MCNP6.1 was achieved by 
multiplying the Monte Carlo results by the quotient of the beam current of the X-ray tube (typically 18.2 mA, or 
equivalently 18.2 mC  s-1) divided by the elementary charge constant (~ 1.602 × 10–19 C).
Average air kerma values, deduced through MC modelling of predicted free-in-air doses to sealed biological 
pathogens, were benchmarked against experimental data measured using a TN31010 Semiflex ionization cham-
ber, and they showed a good  correlation35. MC modelling data at 22.6 cm from the target sample illustrated the 
presence of a significant bremsstrahlung continuum beginning at ~ 10 keV with the expected characteristic peaks 
at ~ 60 keV and ~ 70 keV from L, Kα and Kβ shell transitions in the X-ray source tungsten target. The systematic 
filtration of the radiation beam using the above metals with increasing mass-thicknesses resulted in the removal 
of low-energy bremsstrahlung radiation but maintained the high energy characteristic radiation (Fig. 1a). The 
data in Fig. 1a were obtained via the use of MCNP6.1 ‘f4:p’ photon fluence tallies, binned into 0.5 keV increments, 
that were defined over small volumes of air located just below the position of the filter and were self-normalized 
to the total integrated fluence recorded by that tally over all energy bins.
To account for beam attenuation and loss of dose rate during photon penetration at an increasing liquid depth 
of sample, absolute dose rates as a function of depth were calculated using the same modelling parameters. For 
these calculations, the representative 1 × 1 × 1 cm3 volumes were subdivided into a set of 10 horizontal slices of 
thickness 1 mm, and a MCNP6.1 ‘f6:p’ photon kerma tally was defined over each layer; renormalization to the 
18.2 mA applied beam current of the X-ray tube was then applied to obtain absolute dose rates from the rela-
tive Monte Carlo data. Doses in the first few milliliters of water were found to be significantly larger than those 
at greater depth. The data in Fig. 1b demonstrate that dose gradients are greater for an unfiltered field, due to 
higher intensities of poorly penetrating low-energy photons, but conversely less for more filtered fields, which 
are proportionally harder.
Our MC data of photon energies and beam penetration through the sample packaging predicted an aver-
age dose rate of 0.496 Gy/s (std. dev. ± 0.075) in the geometric field of the X-ray beam (SI Appendix Fig. S1a, b 
and c) and supported confidence in dose uniformity and virus sample exposure levels during radiation cycles. 
Figure 1c illustrates a diagram of the experimental setup including the distance from the modelled X-ray source 
to the virus samples. These sets of data taken together provide key parameters for reproducible inactivation of 
infectious material and can be used to scale inactivation conditions in a reliable manner.
Using ZIKV as an example, the effect of beam hardening by filtration on virus inactivation were exam-
ined using two endpoint readouts of absolute genomic quantification by reverse transcriptase real-time PCR 
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(RT-qPCR) and viral infectivity using the 50% tissue culture infectious dose  (TCID50) assay. Beam harden-
ing experiments were carried out with frozen and liquid/physiological (ambient) sample conditions. D-values, 
defined as the radiation-dose required to reduce the viral infectivity titer by 90% (or 1-log10) were determined 
by the method of Schmidt and  Nank36 using  TCID50 data.
Filtration with 0.3 mm Cu led to the greatest reduction in low-energy bremsstrahlung photons (or soft X-rays) 
and exposed the samples to fields more dominated by the characteristic X-rays. This led to a reduced efficacy 
in ZIKV inactivation, as measured by RT-qPCR (Fig. 1d) and  TCID50 data (Fig. 1e). Unfiltered beam exposure 
produced a similar inactivation curve to that from a beam filtered with 0.2 mm Al but showed higher variability, 
causing inconsistencies across ZIKV inactivation. This data set in combination with predictions obtained from 
the MC modelling data rationalized the use of 0.2 mm Al for beam filtration to ensure a better balance between 
dose uniformity and dose rate attenuation in all subsequent inactivation experiments.
The highest efficacy of viral inactivation was achieved using 0.2 mm Al filtration under ambient conditions 
for ZIKV (D-value 1.83 kGy); beam filtration with 0.3 mm Cu showed a significantly higher D-value (2.94 kGy), 
suggesting that it is the low-energy component of the photon field (below ~ 20 keV) that is the most effective for 
viral inactivation, in turn suggesting a photoelectric mechanism of inactivation. In the context of sample condi-
tions (i.e. frozen or ambient), a similar trend to ZIKV was observed when comparing frozen RVFV (3.84 kGy) 
and ambient (2.63 kGy) conditions using 0.2 mm Al beam filtration. To this end, 0.2 mm Al filtration under 
ambient conditions at 220 keV, 17.5 mA were subsequently used to produce inactivation curves and determine 
D-values for the selected viruses in this study. All doses were identified through pre-set time-dependent radiation 
exposure experiments while absorbed dose was monitored in real-time. From here on, viruses treated with X-rays 
are denoted with the suffix “-X” (e.g. ZIKV-X) with the related exposure dose in kGy indicated in superscript.
D‑values predict non‑infectious ZIKV and RVFV in vitro and in vivo. Following the determination 
of D-values, ZIKV and RVFV sterility were assessed and confirmed via in vitro viability experiments. All inacti-
vation doses were examined for cytopathic effects (CPE) by three consecutive rounds of tissue culture passages 
in Vero cells. Total virus input for all irradiated samples were controlled using RT-qPCR readouts to ensure that 
a minimum of  108 genomic-equivalent copies/mL of X-ray treated virus (pre-irradiation infectious titer of  106 
 TCID50/mL) were added to each cell culture monolayer. This provided assurance that the development of any 
CPE in vitro during the assay was normalized across the X-ray treated samples throughout the course of the 
experiment. As expected, non-irradiated ZIKV and RVFV controls developed CPE in Vero cells at 4 and 3 days 
post-infection respectively. A correlation between the time of delay before CPE and the X-ray dose was observed 
throughout the three-week assay.
Figure 1.  Effect of X-ray beam filtration on ZIKV inactivation. Monte Carlo simulation of beam filtration effect 
on (a) X-ray photon energy spectra showing beam  hardening58,59 and (b) dose-to-depth penetration of photons 
in water at 220 keV, 18.2 mA using MCNP6.1 model in (c) the irradiation chamber showing the sealed virus 
specimens with packaging dimensions of 10 cm × 8 cm × 1 cm (L x W x D) at a distance of 22.6 cm within a 
37.5° irradiation cone produced by the MXR-225/26 tube. Incremental X-ray irradiation of ZIKV at the above 
conditions showing (d) the effect of beam filtration on ZIKV RNA genomic-equivalent copies using RT-qPCR 
and (e) Infectivity titer of ZIKV by  TCID50 assay. All data was acquired by accounting for a sample-to-source 
distance of 22.6 cm and each data point represents the mean of triplicate independent runs.
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Consistent with the D-values predicted from the inactivation curves, a final dose of 12.8 kGy for ZIKV-X 
and 15.79 kGy for RVFV-X as judged by CPE assays produced inactivated virus (Fig. 2a). To investigate sterility 
further, in vivo animal disease models for ZIKV and RVFV were employed to provide additional evidence of 
non-infectious virus using the predicted X-ray inactivation doses. For ZIKV, interferon type-II deficient A129 
mice were intravenously administered with an equivalence of 1 × 106 pfu of irradiated virus (at serial X-ray dose 
increments) and doses ≥ 9 kGy showed a 100% survival rate at 14 weeks post-infection (Fig. 2b). No significant 
clinical symptoms or shifts in animal weights were observed during this period of experimentation, whereas 
mice treated with non-irradiated ZIKV (1 × 105 pfu) and doses ≤ 7.2 kGy consistently presented with clinical 
symptoms and were euthanized (according to pre-set disease end-points and ethical standards) within six days 
post-infection. Similar experiments were performed for RVFV using BALB/c mice with similar results: all mice 
survived after 2 × intramuscular administration of 5 × 105 pfu of inactivated virus (i.e. virus pre-irradiated with 
doses ≥ 14.4 kGy; Fig. 2c). The organs of surviving mice, including blood, spleen, brain and liver were checked for 
the presence of viral genomic material using RT-qPCR and were found to be negative, indicating that the RVFV-X 
treated with doses ≥ 14.4 kGy were no longer replicating and were not infectious in BALB/c mice. D-values for 
HAZV and BEBV were found to be 0.96 and 4.83 kGy respectively.
It was observed that in vitro viability systems are a more sensitive method for determining loss of viral replica-
tion as it permits the sampling of a larger amount of virus for CPE. However, in vitro and in vivo results display a 
good correlation and re-affirm the predictive model of D-values for inferring virus sterility after X-ray irradiation.
Biochemical and immunological characterization of X‑ray inactivated virus. An assessment of 
whether any of the X-ray inactivated viruses could be used as a source of viral RNA/cDNA or protein reagents 
in downstream biochemical and/or immunological assays was next investigated. To this end, ZIKV-X11.6kGy and 
Figure 2.  Inactivation of viral pathogens using X-rays. (a) X-ray D-values showing the dose required to 
inactivate 1-log10 of virus at 220 keV, 17.5 mA with 0.2 mm Al filtration. In vitro CPE was not observed in 
an infection-sensitive cell substrate after treatment with 1 mL of virus and following 3 passages at predicted 
inactivation doses. X-ray D-values were then compared to gamma inactivation data produced under similar 
sample conditions, for members of the same genus. (b) ZIKV infectivity in A129 mice after intravenous 
administration of irradiated ZIKV and (c) RVFV infectivity in BALB/c mice after intramuscular administration 
of irradiated RVFV; data shows 100% survival of mice for receiving viruses that had been irradiated with 
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RVFV-X18.4kGy were utilized in a series of experiments involving Next Generation Sequencing, ELISA and West-
ern blot analysis. Using virus stocks cultivated at ≥ 6  log10 infectious units, the utility of X-ray irradiation under 
ambient conditions for sequencing and full-length assembly of non-replicating ZIKV-X11.6kGy and RVFV-X18.4kGy 
genomes using an Illumina paired-end sequencing library was performed. ZIKV has a positive-sense single-
stranded RNA genome whereas RVFV consists of a tripartite negative-stranded RNA genome consisting of 
Small (S), Medium (M) and Large (L) segments. Using  SPAdes37, it was possible to re-assemble the complete 
genomes of both ZIKV-X and RVFV-X. Genome assembly showed no significant statistical association between 
the N50 variance and increasing X-ray irradiation dose, for either virus (Fig. 3a).
Complete ZIKV-X and RVFV-X S, M and L genomes could be successfully reconstructed from two inde-
pendent non-replicating, X-ray inactivated virus stocks without the need for genome scaffolding. To assess for 
potential mutations incurred from X-rays during inactivation, complete genome assemblies from the non-
irradiated stocks of both viruses were used in the subsequent mapping of irradiated sequencing reads. Mapping 
experiments to the respective viral genomes showed a minimum of ×500 depth of coverage (Fig. 3bi–iv) for both 
viral species across all X-ray irradiation doses. Mutations were assessed by calling variants at a coverage depth 
of ≥ ×100 and Phred quality score 30, against the final assembly of non-irradiated ZIKV and RVFV genomes. 
Figure 3C shows genomic segments of both inactivated ZIKV-X and RVFV-X containing random counts of 
substitution mutations, interestingly however no correlations were observed between dose exposure and the 
number of variants per genome segment(s) of either virus. As all viral stocks used in these sets of experiments 
originated from a single batch, it is unlikely that the observed variants are from variations in viral propagation or 
cultivation conditions. It is however probable that these variants are a result of either the mutation rate associated 
with MLV reverse-transcriptase used during cDNA  synthesis38 or the proof-reading actions associated with Taq 
polymerase enzyme during NGS library amplification steps rather than X-ray irradiation.
With respect to protein analysis of X-ray inactivated material, ZIKV-X envelope glycoprotein (Fig. 3d) and 
RVFV-X nucleoprotein (data not shown) were detected by Western blot using commercially sourced polyclonal 
antibodies at a similar sensitivity to that found for non-irradiated viral extracts. Matched tissue culture superna-
tants without propagated virus served as negative controls for the antibodies and did not show cross-reactivity 
with non-viral antigens. Employing an independent approach, a commercially sourced multi-species competition 
ELISA kit was adapted to assess the protein integrity of X-ray irradiated RVFV. Serum samples were replaced with 
irradiated virus preparations and crude non-irradiated C6/36 lysate served as negative control. Figure 3E shows 
that a 1:10 dilution of all irradiated virus preparations effectively inhibited the interaction of anti-NP antibody 
whereas C6/36 lysate did not (Fig. 3e). To affirm specificity of interaction, serial dilutions of irradiated RVFV 
treated with an 18.2 kGy dose was used as competition substrate for anti-NP (Fig. 3f).
Figure 3.  Nucleic acid and protein analysis of X-ray inactivated virus. (a) Box plot of N50 contig assembly 
statistics for RVFV and ZIKV, showing no statistical differences (Mann–Whitney U, two-sided) between 
viral contig re-assembly across radiation doses (0 to 24 kGy), (b) NGS mapping data demonstrating similar 
depth of coverage when comparing sequencing of non-irradiated and irradiated ZIKV-X and RVFV-X and 
(c) regression analysis of variants induced through X-ray irradiation across dose increments, showing non-
significant correlations (r2 ≤ 0.32 ). The effect of irradiation on viral proteins by (d) Western blot detection of 
ZIKV envelope illustrating uniform sensitivity of detection, (e) abrogation of competition ELISA signal of 
RVFV anti-NP using X-ray irradiated antigen (n = 3 per dose). (f) two-fold serial dilutions of whole-virus RVFV 
irradiated with 18.2 kGy of X-rays inhibits the binding of anti-NP in commercially sourced competition ELISA.
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Discussion
Zoonotic infections have been the predominant source of dangerous emerging disease over the last  century9,39 and 
include EVD, CCHF, Lassa fever, RVF, MERS and SARS. Work with such zoonotic pathogens requires the use of 
specialized high-containment facilities necessary for the safe handling of infectious materials. A consequence of 
the stringent bio-safety features of these facilities, especially BSL4, is a constraint to high-throughput processing 
which in turn slows the progress of diagnostic reference virology, including R&D work. While many microbio-
logical activities can be accommodated within BSL4, there are significant practical and cost benefits of being 
able to work outside of containment by effectively inactivating pathogens. However, standard and established 
methods of virus inactivation such as heat treatment or chemical cross-linking with formaldehyde destroy and/
or modify complex protein structures and can lead to decreased sensitivity or artefactual results. This is especially 
problematic if inactivated pathogens are being used for clinical diagnosis and reference virology. A potential solu-
tion is to inactivate with X-rays which does not destroy native antigenic structure and provides a useful route to 
delivering non-infectious reagents for diagnostics and R&D work in lower containment laboratories and provides 
comparable results to non-inactivated native material. The production of non-infectious material containing 
whole-virus characteristics is a distinct advantage as it supports more complex experimental strategies than can 
be achieved with chemically modified or heat-denatured inactivated viral material. A number of studies examin-
ing the parameters that influence direct or indirect mechanisms of viral inactivation such as, sample types and 
suspension  matrices40–44, physiological temperature  states45, particle size and infectious  titer46 have all indicated 
that X-ray irradiation could rapidly advance and strengthen conventional public health laboratory activities, and 
should therefore be considered as a serious contender to the current gold standard radiological sources such as 
Cobalt-60 for agents requiring BSL3/BSL4 facilities. However, to our knowledge, a detailed study with accurate 
D-values showing evidence of inactivation of viruses that retain biological and immunological characteristics 
using X-rays has not been thus far demonstrated. Guided by MC modeling, the data reported here shows the 
amount and type of X-ray radiation required for effective inactivation of viruses belonging families that cause 
medically-important zoonotic infections in humans. It was possible to recover nucleic acid for sequencing post 
inactivation and the protein moieties were detected in routine laboratory analysis.
X-rays offer unique advantages over conventional gamma ray inactivation as they permit higher levels of 
control over the delivery of beam uniformity to a pathogenic specimen. Although gamma sources such as 
Cesium-137 or Cobalt-60 can offer very high dose rates compared to the output of typical X-ray tubes, they 
have significant drawbacks, such as highly divergent fields and inherent difficulties in controlling dose rates and 
inactivation. Furthermore, gamma source security, shielding, decommissioning and management introduce a 
range of addition non-scientific problems which are not simple to address. In contrast, X-ray sources are more 
controllable and directional, permitting improved accuracy in the dose uniformity ratio and in the inactivation 
process, consequently they reduce the risk of unnecessary damage to the material. This resolution in uniformity 
can be controlled using choice filtration composites with appropriate attenuation properties for lower energy 
photons. This is an important factor in the context of developing and scaling X-ray inactivated viruses for 
rapid diagnostics, high resolution structural biology or potentially for emergency vaccines which can be rapidly 
 inactivated47–49 to support front-line healthcare workers in HCID outbreaks.
Initial experiments focused on determining the optimum dose required for a 1-log10 reduction in virus titer 
under frozen and ambient (18˚C) conditions. A comparison of the two conditions showed that protein and 
nucleic acid characterization could be achieved in both cases. However, physiological conditions permitted 
quicker inactivation by a few orders of magnitudes as defined by D-values, consistent with previous inactiva-
tion reports using gamma and X-ray irradiation of viruses in different matrices including those containing high 
protein concentrations or in animal tissues such as brain and  blood20,50–53.
Filtration permits the removal of soft X-rays (≤ ~ 20 keV) by a reduction of bremsstrahlung continuum pho-
tons in the X-ray beam. In our experiments looking at the effect of filtration on the irradiation of ZIKV, 0.3 mm 
Cu filtration produced inefficient inactivation of virus under both ambient (-3.8 log reduction) and frozen (-2.8 
log reduction) sample conditions; this compared to -6.6 log reductions for the unfiltered or 0.2 mm Al filtered 
X-ray doses. These data taken together, suggest that X-ray energies lying on the hard X-ray electromagnetic 
spectrum are less responsible for inactivation and that soft X-rays are more accountable for the inactivation of 
viruses through a specific photoelectric ionization mechanism. Filtration of X-rays using 0.3 mm Cu resulted in 
a significant loss in dose rate which would have to be compensated for by a longer cycle of irradiation to achieve 
the required dose. On the other hand, unfiltered X-ray beams showed enhanced variability both in the context 
of depth-to-dose penetration of X-rays within the liquid phase of the samples as well as across the sample plane. 
Irradiation under these conditions would result in over-exposure of the samples to achieve assurance that the 
required dose had been used for sample inactivation. Filtration using 0.2 mm Al permitted the penetration of 
soft X-rays across the packaging system of our samples and induced sample inactivation with decimal reduction 
values comparable to the literature (Fig. 2a). Furthermore, 0.2 mm Al filtration permitted uniform exposure of the 
samples to predicted X-ray doses required for inactivation. These parameters showed the successful inactivation 
of ZIKV, BEBV, HAZV and RVFV under ambient conditions.
An accurate understanding of doses required for sample inactivation using D-values is useful for normalizing 
exposure times relative to infectious titer and, in turn, will prevent unnecessary damage to precious samples 
following prolonged irradiation procedures. These D-values can be achieved with current plug and play instru-
mentation such as the MultiRad 225 keV, which provides highly penetrative irradiation doses permitting viral 
inactivation through stringent sample packaging systems. Through selection of composite materials with low 
X-ray attenuation coefficients or high Z-values for sample packaging, it may be possible to focus the desired pho-
ton energies responsible for inactivation of the pathogen and reduce irradiation times further. Higher dose rates 
can be achieved by considering dual or triple X-rays sources which could reduce the exposure time significantly 
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and achieve uniform sample inactivation. The sources are relatively straight forward to operate locally and are 
much safer than radioisotopes because they do not generate nuclear waste or require such stringent security 
and protective measures.
In principle, it has been demonstrated here that X-ray inactivation can be successfully achieved for a selection 
of medically-important zoonotic viruses. X-ray irradiation is an effective mode of pathogen inactivation, which 
permits the production of non-infectious whole virus material that retains desired biochemical and immunologi-
cal properties under ambient inactivation conditions. Preparedness in conjunction with active bio-surveillance 
programs are crucial public health endeavors and X-ray irradiation offers a unique tool for rapidly developing 
reagents for a range of downstream applications in a safe and reproducible manner.
Materials and methods
Virus stocks and cell lines. The following virus-cell systems were used for virus cultivation. Zika virus 
(ZIKV) African strain MP1751 (NCPV accession 1308258v) was cultured at 37 °C, 5%  CO2 for 3 days in Vero 
cells (ECACC accession 84113001) using MEMα media supplemented with 10% fetal bovine serum (FBS). Haz-
ara virus (HAZV) strain JC280 was cultured at 37  °C, 5%  CO2 for 6 days in SW13 cells (ECACC accession 
87031801) using MEMα-10% FBS. Bebaru virus (BEBV) was cultivated at 37 °C, 5%  CO2 for 2 days in BHK21 
clone 13 cells (ECACC accession: 85011433) using MEMα-10% FBS. Rift Valley Fever virus (RVFV) strain 
ZH501 was cultured at 28 °C for 5 days in C6/36 cells (ECACC accession 89051705) in MEMα-10% FBS supple-
mented with 1.1 g/L of  NaHCO3 in the absence of  CO2. Virus stocks were cultivated in single batches of 150 mL 
each, using the Nunc TripleFlask system (ThermoFisher, UK) prior to clarification by centrifugation at 6,000 × g, 
4 °C. Each of the virus species were then aliquoted in to 1 mL working stocks and frozen in preparation for pre-
irradiation titration and all subsequent irradiation runs. Titration of virus infectivity pre- and post-irradiation 
was performed by  TCID50 titration using the Spearman-Kärber calculation.
Monte Carlo modelling of X‑ray photons. MC simulations were performed using the general-purpose 
radiation transport code MCNP6.154. The model accounts for X-ray source tube potential and current, distance 
to samples, geometric field of exposure including packaging materials and densities used during irradiation. 
The source was modelled as a 2.75 mm radius beam of plane-parallel monoenergetic electrons impinging on an 
angled target of pure tungsten of density 19.6 g/cm3. The beam was orientated along the negative x-axis and was 
hence perpendicular to the vertical (z) axis of the irradiation chamber. In general, the physics parameters and 
models used in the Monte Carlo simulations were the defaults applied by MCNP6.1, which are the code’s maxi-
mally accurate options in almost all cases; the MCPLIB84 and e103 cross-section libraries were used for photons 
and electrons respectively. In order to improve computational efficiency, however, production of bremsstrahlung 
photons in the tungsten was artificially enhanced by setting the BNUM parameter in MCNP to 10,000, with 
the code then re-weighting the results automatically to maintain fairness; whilst the exact choices of variance 
reduction applied in the modelling were chosen ‘by hand’, and may not necessarily be optimal, it is important 
to emphasize that all tally results were successfully tested for statistical robustness using the packages applied 
by MCNP6.1 by default. Photon intensities and doses were determined using MCNP f4 fluence- and f6 kerma-
tallies, respectively, with the latter justified under the reasonable assumption of secondary charged particle equi-
librium at the locations of interest.
X‑ray irradiation and inactivation. Commercial X-ray generators typically operate by impinging a beam 
of electrons onto a high-Z target (often tungsten) inside an evacuated tube. As the electrons decelerate within the 
target, bremsstrahlung photons are emitted with a directional distribution that is dependent on the target mate-
rial and its shape, as well as on the energy of the incident electrons. A thin window in the X-ray tube allows the 
photons to escape, with collimation typically added around the window to better focus the direction of the beam 
and prevent the escape of stray radiation. The energy distributions of the X-ray beams are composed of continu-
ous bremsstrahlung radiation that is dependent on the voltage of the electron beam and characteristic peaks that 
occur at energies dependent on the material. The overall intensity of the X-ray field is governed by the electron 
beam current. Beam filtration using metals with increasing attenuation coefficients and/or densities can be used 
to systematically remove the lower energy components of the photon fields, resulting in beam hardening.
X-ray irradiation was performed on a MultiRad 225 keV X-ray Irradiator (Precision X-rays, USA) fitted 
with an MXR-225/26 X-ray source (225 kV 4 k W). Irradiation dose–response inactivation curves for ZIKV and 
RVFV were developed for frozen and ambient (18˚C) temperatures. BEBV and HAZV were inactivated under 
ambient conditions. All virus data were developed by conducting independent irradiation cycles in triplicate. 
To achieve this, virus supernatant volumes of 1 mL were heat-sealed within 2 layers of heavy-duty polyethylene 
plastic sheets (500 gauge thick) and treated with 1.8 kGy incremental doses of X-rays to a final dose of 50 kGy. 
The D-values were calculated as described by Schmidt and  Nank36 by calculating the gradient of the linear 
regression-fitted model as a function of log dose vs. log infectious viral titer ( N − N0 ), where N is X-ray treated 
virus and N0 is untreated.
Sterility of irradiated ZIKV and RVFV in vitro and in vivo. All X-ray treated and non-treated ZIKV 
and RVFV samples were passaged for 3 rounds in vitro in T-12.5 vessels using Vero cells (1 mL of virus/flask, 
n = 3 per dose) for 7 days per round. Infectious split transfers of 50% cells and culture supernatant were per-
formed at weekly intervals for a period of 3 weeks to define sterility. CPE were monitored daily. IFN-α/β receptor 
deficient A129 mice (n = 28, 2 mice per radiation dose) and BALB/cOlaHsd 6–8-week-old mice (n = 28, 2 mice 
per irradiation dose) were used for ZIKV and RVFV sterility studies respectively. The in vivo work was under-
taken according to the United Kingdom Animals (Scientific Procedures) Act 1986. These studies were approved 
8
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21431  | https://doi.org/10.1038/s41598-020-77972-5
www.nature.com/scientificreports/
by the ethical review process of Public Health England, Porton Down, UK, and by the Home Office, UK. A set of 
humane end-points based on clinical manifestation of disease was defined in the protocol of the project license. 
A129 mice were administered intravenously with 400 µL of irradiated ZIKV or non-irradiated control. BALB/c 
mice were administered intramuscularly with 2 × 50 µL of irradiated RVFV or non-irradiated control.
RNA isolation and reverse‑transcriptase qPCR. Viral RNA was isolated as per the manufacturer’s 
instructions using the QIAamp viral RNA isolation kit (Qiagen, UK). All RT-qPCR assays were expressed as 
genomic copy equivalents using a synthetic RNA control transcript (IDT, UK). Quantification of RVFV RNA 
in mice brain, spleen and liver tissues in the pathogenesis study were normalized to tissue weight. ZIKV assays 
were performed as per the Lanciotti  assay55 and RVFV assays were performed as per the Drosten  assay56 using 
SuperScript III One-Step RT-PCR kit (Thermo-Fisher, UK).
Western blot analysis. A 100 µL of irradiated or control ZIKV at 1 × 106 TCID50/mL were concentrated 
using AmiconR Ultra 0.5 centrifugal filters (Millipore, UK) at 14,000 × g for 30 min and resuspended in 30 µL of 
lithium dodecyl sulfate (LDS) sample buffer containing 50 mM DTT (Invitrogen, UK). Mock infected Vero cell 
lysate (pellet and clarified supernatant) served as negative control. Protein electrophoresis was performed using 
NuPAGE Bolt 12% Bis–Tris Plus Gels, 10-well-10 gels (ThermoFisher, UK) at 200 V for 35 min. Electrophoresed 
proteins were transferred on to ethanol-activated 0.2 µm PVDF membranes using a wet transfer system at 20 V 
for 60 min and probed with Zika virus Envelope protein antibodies (GeneTex, USA). HRP secondary antibody 
was detected with 1-Step Ultra TMB-Blotting Solution (ThermoFisher, UK). Mock infected Vero cell lysate (pel-
let and supernatant) served as negative control. Blot Images were captured on a white light pad fitted to a G:Box 
F3 using standard settings of their GeneSys analysis software version 1.7.2 (Syngene, UK). Further details can be 
found in SI Appendix Fig. S4.
Next Generation Sequencing. Total nucleic acid was isolated using QIAamp viral RNA Mini Kit (Qia-
gen, UK) from each irradiated sample as per the manufacturer’s instructions. An aliquot of the total nucleic 
acid (45 µL) was treated with Turbo DNAse I (Invitrogen, UK) following the manufactures instructions and 
then purified using an RNA Clean and Concentrator—5 kit (Zymo Research, USA). This material was then 
used in second strand cDNA synthesis using a random nonamer primer A and amplified using primer B using 
AccuTaq LA DNA Polymerase (Sigma, UK) as previously  described57. The PCR conditions were set to 98 °C for 
30 s denaturation, 30 cycles of 94 °C for 15 s, 50 °C for 20 s, and 68 °C for 10 min. Amplified cDNA was purified 
using a 1:2 ratio of AMPure XP beads (Beckman Coulter, USA) and quantified using a Qubit and High Sensitiv-
ity dsDNA Kit (ThermoScientific, UK). A 2 × 150 bp paired-end Illumina sequencing library was prepared using 
the Nextera XT V2 Kit with 1.5 ng of cDNA as the input, following the manufacturer’s instructions. Indices were 
selected using the Illumina experiment manager and sequenced on an Illumina MiSeq by the Central Sequenc-
ing Laboratory, Public Health England.
Genome assembly and variant calling. ZIKV and RVFV genome assembly for each irradiation condi-
tion was performed using SPAdes version 3.13.0. Assembly statistics were assessed using Quast version 5.0.2 and 
are presented as N50 values representing the length of the shortest contig at 50% of the total genome length for 
ZIKV and RVFV. Depth of coverage for each irradiation time point was performed using BWA version 0.7.12-
r1039 and the respective non-irradiated control virus as a reference (ZIKV strain MP1751 and RVFV strain 
ZH-501). Final consensus determination for each irradiation time point was performed using Pilon version 1.22 
using a k-mer of 15. Variants were called using BCFtools MPileup version 0.1.19 at a depth of 100 and Phred 30.
Competition enzyme‑linked immunosorbent assay. Competition ELISA was performed using ID 
Screen Rift Valley Fever Competition Multi-species ELISA (ID.Vet, France). This assay allows testing of human/
animal sera for antibodies to RVFV nucleoprotein (NP) antigen on a solid-phase surface. A 1:10 dilution of 
X-ray irradiated whole virus preparation (equivalent to 3.0 × 105 pfu/mL) was pre-incubated with the kits com-
petition reagents conjugated to HRP in place of immune sera. The assay was then developed following the manu-
facturer’s instructions. To confirm specificity irradiated viral antigen abrogating the ELISA signal, twofold serial 
dilutions of inactivated RVFV prepared using 18.2 kGy of radiation was pre-mixed with the kits competition 
HRP reagent. Absorbance was measured at 450 nm. Absorbance signal was plotted against a natural log trans-
formation of twofold serial dilutions to express the relationship of irradiated antigen specificity. All figures and 
graphs were prepared using GraphPad Prism version 7.05.
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